Results 31 to 40 of about 28,403 (261)

Evaluation of stroke risk associated with the use of typical or atypical antipsychotics among patients with cardiovascular diseases

Journal of Medical Sciences, 2015
Background: Concerns regarding stroke safety associated with the use of atypical antipsychotics among dementia patients have been raised. Although observational studies have found conflicting associations of stroke risk with the use of typical or ...
Meng-Ting Wang, Min-Fang Li, Che-Li Chu, Chin-Bin Yeh, Cheng-Liang Tsai, Jun-Ting Liou   +5 more
doaj   +1 more source

Antipsychotics use in dementia: How safe are they?

European Psychiatry, 2021
Introduction Antipsychotics are frequently used for managing psychiatric and behavioral symptoms of dementia. However, it’s an off-label resource which remains controversial due to significant safety concerns in the elderly population, namely ...
C. Lopes
doaj   +1 more source

Asenapine versus other atycipal antipsychotics for schizoaffective disorder Case study

European Psychiatry
Introduction Antipsychotics are psyschotropic medications that are indicated for the treatment of physchosis and mood disorders. Due to minimal side effects and their efficacy (affecting many receptors) compared to standard antipsychotics, today ...
E. Shaska
doaj   +1 more source

The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia

Biomedicines, 2023
Catalytic antibodies, or abzymes, are capable of not only binding but also hydrolyzing various proteins. Previously, an increase in the level of myelin basic protein (MBP)-hydrolyzing activity of antibodies was shown in patients with a number of ...
Daria A. Kamaeva, Daria V. Kazantseva, Anastasiia S. Boiko, Irina A. Mednova, Liudmila P. Smirnova, Elena G. Kornetova, Svetlana A. Ivanova   +6 more
doaj   +1 more source

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis – results to be interpreted with caution [PDF]

, 2010
Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic ...
Goikolea, José Manuel, Krishnadas, R., Vieta i Pascual, Eduard, 1963-, Valentí Ribas, Marc, Sánchez-Moreno, José, Torres, Ferran, Livingston, M., Cruz, Nuria   +7 more
core   +1 more source

The role of atypical antipsychotics in the treatment of schizophrenia

, 2023
Schizophrenia is a complex mental disorder that consists of positive, negative, and cognitive symptoms that can have a significant impact on an individual's quality of life and social functioning.
Abo Asalh, Rand
core  

Atypical antipsychotics and sexual functions in schizophrenia: A cross-sectional study

Annals of Indian Psychiatry
Background: Antipsychotics are associated with sexual dysfunction. However, studies selectively exploring the sexual impact of atypical antipsychotics in a standardized male population are limited, and further more in the Indian context. Thus, a need was
Charanpreet Singh, Rachit Sharma, C Rakesh   +2 more
doaj   +1 more source

Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents

Pharmaceuticals, 2020
This is a comprehensive review of the literature on drug interactions (DIs) between atypical antipsychotics and anti-infective agents that focuses on those DIs with the potential to be clinically relevant and classifies them as pharmacokinetic (PK) or ...
Edoardo Spina, Maria Antonietta Barbieri, Giuseppe Cicala, Jose de Leon   +3 more
doaj   +1 more source

Negative and Cognitive Symptoms of Schizophrenia: Are there Adequate Pharmacological Treatments?

European Psychiatry, 2022
Introduction The ongoing debate regarding the treatment efficacy for negative and cognitive symptoms in schizophrenia is a subject of continuous frustration among psychiatrists.
O. Vasiliu
doaj   +1 more source

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database [PDF]

, 2013
Background: Drug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden. Objective: As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US ...
MORETTI, Ugo, De Ponti F., Sturkenboom, M, Sturkenboom, M.C.J.M. (Miriam), De Ponti, F, Behr, E.R. (Elijah), Koci A, Spina, E, Sturkenboom M, Ariola Koci, Poluzzi E, Spina E, Raschi, E. (Emanuel), Ponti, F. (Fabrizio) de, Ugo Moretti, Spina, E. (Edoardo), Poluzzi, E, POLUZZI, ELISABETTA, Koci, A. (Ariola), Behr ER, Koci, A, Elijah R. Behr, Elisabetta Poluzzi, Poluzzi, E. (Elisabetta), Sturkenboom, MCJM, Moretti, U. (Ugo), Fabrizio De Ponti, KOCI, ARIOLA, Moretti, U, Emanuel Raschi, Raschi, E, Miriam Sturkenboom, DE PONTI, FABRIZIO, Moretti U, RASCHI, EMANUEL, Behr, ER, Raschi E, Edoardo Spina   +37 more
core   +1 more source